The Effect of Dipyridamole and RA 233 on Human Platelet Function in Vitro

Paul L. Rifkin; Marjorie B. Zucker

doi:10.1055/s-0038-1648112

Thrombosis and Haemostasis, Table of Contents

Thromb Haemost 1973; 29(03): 694-700
DOI: 10.1055/s-0038-1648112

Original Article

Schattauer GmbH

The Effect of Dipyridamole and RA 233 on Human Platelet Function in Vitro

Authors

Paul L. Rifkin

¹Departments of Medicine and Pathology New York University School of Medicine, N. Y., N. Y. 10016
Marjorie B. Zucker

¹Departments of Medicine and Pathology New York University School of Medicine, N. Y., N. Y. 10016

Abstract

Summary

Dipyridamole (Persantin) is reported to prolong platelet survival and inhibit embolism in patients with prosthetic heart valves, but its mechanism of action is unknown. Fifty jxM dipyridamole failed to reduce the high percentage of platelets retained when heparinized human blood was passed through a glass bead column, but prolonged the inhibition of retention caused by disturbing blood in vitro. Possibly the prostheses act like disturbance. Although RA 233 was as effective as dipyridamole in inhibiting the return of retention, it was less effective in preventing the uptake of adenosine into erythrocytes, and more active in inhibiting ADP-induced aggregation and release. Thus there is no simple relation between these drug effects.

Full Text

References

References
1 Acheson J, Danta G, Hutchinson E. C. 1969; Controlled trial of dipyridamole in cerebral vascular disease. British Medical Journal 01: 614.
2 Bowie E JW, Owen Jr C. A, Thompson Jr J. H, Didisheim P. 1969; Platelet adhesiveness in von Willebrand’s disease. American Journal of Clinical Pathology 52: 69.
3 Browse N. L, Hall J. H. 1969; Effect of dipyridamole on the incidence of clinically detectable deep-vein thrombosis. Lancet 02: 718.
4 Coller B. S, Zucker M. B. 1971; Reversible decrease in platelet retention by glass bead columns (adhesiveness) induced by disturbing the blood. Proceedings of the Society for Experimental Biology and Medicine 136: 769.
5 Cucuianu M. P, Nishizawa E. E, Mustard J. F. 1971; Effect of pyrimidopyrimidine compounds on platelet function. Journal of Laboratory and Clinical Medicine 77: 958.
6 Eliasson R, Bygdeman S. 1969; Effect of dipyridamole and two pyrimidopyrimidine derivatives on the kinetics of human platelet aggregation and on platelet adhesiveness. Scandinavian Journal of Laboratory and Clinical Investigation 24: 145.
7 Emmons P. R, Harrison M JG, Honour A. J, Mitchell J RA. 1965; Effect of dipyridamole on human platelet behaviour. Lancet 02: 603.
8 Friedberg N. M, Zucker M. B. 1972; ADP as the cause of reversible inhibition of platelet retention in glass bead columns. Journal of Laboratory and Clinical Medicine 80: 603.
9 Gent A. E, Brook C GD, Foley T. H, Miller T. N. 1968; Dipyridamole: a controlled trial of its effect in acute myocardial infarction. British Medical Journal 04: 366.
10 Gray G. R, Wilson P. A, Douglas A. S. 1968; The effect of dipyridamole on platelet aggregation and adhesiveness. Scottish Medical Journal 13: 409.
11 Harker L, Slichter S. J. 1970; Studies of platelet and fibrinogen kinetics in patients with prosthetic heart valves. New England Journal of Medicine 283: 1302.
12 Hellem A. J, Ødegaard A. E, Skâlhegg B. A. 1963; Investigation on adenosine diphosphate (ADP) induced platelet adhesiveness in vitro. Part 1. The ADP-platelet reaction in various experimental conditions. Thrombosis et Diathesis Haemorrhagica 10: 61.
13 Horch U, Kadatz Z, Ritschard J, Weissenberger H. 1970; Pharmacology of dipyridamole and its derivatives. Thrombosis et Diathesis Haemorrhagica. Suppl. 42: 253.
14 Mayne E. E, Bridges J. M, Weaver J. A. 1969; The effect of dipyridamole on increased levels of platelet aggregation and adhesion. Journal of Atherosclerosis Research 09: 335.
15 Mills D CB, Smith J. B. 1971; The influence on platelet aggregation of drugs that affect the accumulation of adenosine 3’5’ cyclic monophosphate in platelets. Biochemical Journal 121: 185.
16 Myhre E, Hellem A. J, Stormorken H, Rootwelt K. 1971; Intravascular haemolysis, platelet consumption, and platelet adhesiveness in patients with prosthetic heart valves. Scandinavian Journal of Thoracic and Cardiovascular Surgery 05: 13.
17 Rifkin P. L, Friedberg N. M, Zucker M. B. 1973 The effect of apyrase on platelet retention in normal subjects and in patients with abnormal cardiac valves or with Von Wille-brand’s disease. Thrombosis et Diathesis Haemorrhagica. (in press)
18 Rozenberg M. C, Holmsen H. 1968; Adenine nucleotide metabolism of blood platelets. II. Uptake of adenosine and inhibition of ADP induced platelet aggregation. Biochimica et Biophysica Acta 155: 342.
19 Sullivan J. M, Harken D. E, Gorlin R. 1968a Pharmacologic control of thromboembolic complications of cardiac-valve replacement. A preliminary report. New England Journal of Medicine 279: 576.
20 Sullivan J. M, Harken D. E, Gorlin R. 1971; Pharmacologic control of thromboembolic complications of cardiac-valve replacement. New England Journal of Medicine 284: 1391.
21 Sullivan J. M, Kagnoff M. F, Gorlin R. 1968b Reduction of platelet adhesiveness in patients with coronary disease. American Journal of the Medical Sciences 255: 292.
22 Zucker M. B, Peterson J. 1970; Effect of acetylsalicylic acid, other nonsteroidal antiinflammatory agents, and dipyridamole on human blood platelets. Journal of Laboratory and Clinical Medicine 76: 66.